Free tool
FAERS Monitor: Finacea
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021470 or its brand name (Finacea, Azelaic Acid). Reports on generic versions are filed under their own applications.
Reports
841
Serious
445
53% of reports
Hospitalization
168
Death reported
84
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective154
- pain131
- off label use118
- abdominal pain upper110
- vomiting110
- product use in unapproved indication103
- gastrooesophageal reflux disease102
- paraesthesia102
- migraine101
- memory impairment99
- hypoaesthesia98
- rash96
- blepharospasm95
- taste disorder93
- drug intolerance91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 20 |
| 2016 | 17 |
| 2017 | 12 |
| 2018 | 23 |
| 2019 | 31 |
| 2020 | 60 |
| 2021 | 67 |
| 2022 | 70 |
| 2023 | 85 |
| 2024 | 134 |
| 2025 | 139 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,318 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blepharospasmSignal | 95 | 383.0 | 316.4 | 35,282 |
| taste disorderSignal | 93 | 115.2 | 95.0 | 10,374 |
| gastrooesophageal reflux diseaseSignal | 102 | 31.7 | 26.4 | 3,012 |
| migraineSignal | 101 | 26.5 | 22.1 | 2,460 |
| drug intoleranceSignal | 91 | 23.6 | 19.4 | 1,952 |
| memory impairmentSignal | 99 | 18.0 | 15.0 | 1,585 |
| hypoaesthesiaSignal | 98 | 16.4 | 13.6 | 1,409 |
| paraesthesiaSignal | 102 | 16.2 | 13.5 | 1,452 |
| abdominal pain upperSignal | 110 | 13.4 | 11.2 | 1,258 |
| product use in unapproved indicationSignal | 103 | 10.4 | 8.7 | 875 |
| vomitingSignal | 110 | 5.9 | 4.9 | 448 |
| rashSignal | 96 | 5.5 | 4.6 | 357 |
| painSignal | 131 | 5.3 | 4.6 | 471 |
| off label useSignal | 118 | 3.4 | 2.9 | 203 |
| drug ineffectiveSignal | 154 | 2.9 | 2.5 | 206 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.